Prevent hypoglycaemia when using automated insulin delivery systems in type 1 diabetes requires near normal glycaemic variability
Authors:
- 22 November 2024
- journal article
- research article
- Published by Elsevier in Diabetes & Metabolism
- Vol. 51 (1) , 101589
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Open-Source Automated Insulin Delivery in Type 1 DiabetesNew England Journal of Medicine, 2022
- Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled studyThe Lancet Diabetes & Endocrinology, 2022
- Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trialThe Lancet Digital Health, 2022
- Randomized Crossover Comparison of Automated Insulin Delivery Versus Conventional Therapy Using an Unlocked Smartphone with Scheduled Pasta and Rice Meal Challenges in the Outpatient SettingDiabetes Technology & Therapeutics, 2020
- Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 DiabetesNew England Journal of Medicine, 2019
- Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and managementThe Lancet Diabetes & Endocrinology, 2019
- Glycaemic variability in diabetes: clinical and therapeutic implicationsThe Lancet Diabetes & Endocrinology, 2019
- Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trialThe Lancet, 2018
- The glycemic triumvirate and diabetic complications: Is the whole greater than the sum of its component parts?Diabetes Research and Clinical Practice, 2012
- Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 DiabetesNew England Journal of Medicine, 2010